| Changes in Burnout and Satisfaction With Work-Life Balance in Physicians and the General US Working Population Between 2011 and 2014 | Mayo Clinic Proceedings | 2015 | 1.4K |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma | New England Journal of Medicine | 2015 | 928 |
| Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study | Lancet Oncology, The | 2015 | 832 |
| Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma | Nature Medicine | 2015 | 707 |
| Epidemiology of venous thromboembolism | Nature Reviews Cardiology | 2015 | 498 |
| Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Blood | 2015 | 426 |
| Rituximab for IgG4-related disease: a prospective, open-label trial | Annals of the Rheumatic Diseases | 2015 | 398 |
| Diagnosis of monoclonal gammopathy of renal significance | Kidney International | 2015 | 261 |
| CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia | Leukemia | 2015 | 259 |
| Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation | Biology of Blood and Marrow Transplantation | 2015 | 253 |
| Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis | Journal of the American College of Cardiology | 2015 | 250 |
| Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial | JAMA Oncology | 2015 | 242 |
| A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis | New England Journal of Medicine | 2015 | 219 |
| Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research | Biology of Blood and Marrow Transplantation | 2015 | 214 |
| Myeloproliferative Neoplasms: A Contemporary Review | JAMA Oncology | 2015 | 195 |
| Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group | Leukemia | 2015 | 171 |
| Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management | American Journal of Hematology | 2015 | 166 |
| Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 | American Journal of Hematology | 2015 | 160 |
| Smoldering multiple myeloma | Blood | 2015 | 159 |
| Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy | Molecular Immunology | 2015 | 152 |
| Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma | Blood | 2015 | 148 |
| Evolving landscape in the management of transthyretin amyloidosis | Annals of Medicine | 2015 | 134 |
| Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors | Blood Cancer Journal | 2015 | 129 |
| Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia | Blood Cancer Journal | 2015 | 123 |
| Interpretation of cytogenetic results in multiple myeloma for clinical practice | Blood Cancer Journal | 2015 | 121 |
